IGHE and autoimmune thyroid disease: Although it has been observed that a typical type IIb CSU patient is frequently characterized by low IgE and autoimmune thyroiditis [21], whether thyroid autoimmunity alone may predict a poor or absent response to omalizumab in clinical practice has not been clearly defined so far.